Loading... Please wait... Loading... Please wait...
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Pear Therapeutics (NASDAQ: PEAR ) stock is falling on Friday after the company's recent bankruptcy filing continues to weigh on its shares. Pear Therapeutics announced its bankruptcy filing while mark...
Pear Therapeutics (NASDAQ: PEAR ) stock is climbing higher on Tuesday despite the company's plans to explore strategic alternatives. That news was first announced by the company before markets opened ...
The heavy selling pressure might have exhausted for Pear Therapeutics, Inc. (PEAR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St...
Pear is focusing on its established substance abuse products now, putting development on a hold. Performance has been good into onboarding payors that have good coverage in markets where substance abu...
Pear Therapeutics Inc. (NASDAQ:PEAR ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Meara Murphy – Senior Director-Corporate Communications Corey McCann – Pres...
BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today reported r...
Lots of payors are adding reSET to their covered benefit plans, and savings results far exceed prices of the products, usually leaving about 50% in surplus for the health system. Payor contract econom...
Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - Gener...
Pear Therapeutics (PEAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season....
